While artificial intelligence has long supported higher education research initiatives, it’s now expanding into areas that touch student data. Examples include face recognition in surveillance cameras ...

A methodological change contributed to a better-than-expected inflation report, prompting questions from some economists. By Ben Casselman An obscure methodological change lowered a key measure of ...

Abstract: The core of array ultrasonic full matrix data inspection lies in establishing a theoretical model of full matrix data. Existing theoretical models generally assume that the tested specimen ...

Residents also oppose a data center the size of 18 Walmarts that is set to be built in pristine woodland outside Bessemer, Ala. “All this will be gone,” one said. The woodland around Bessemer, Ala., ...

TL;DR: Elon Musk says the algorithm that determines what appears in each user's X feed will be made public within a week – a move he claims will bring transparency to the platform's inner workings.

Jan 10 (Reuters) - Elon Musk said on Saturday that social media platform X will open to the public its new algorithm, including all code for organic and advertising post recommendations, in seven days ...

Shortest path algorithms sit at the heart of modern graph theory and many of the systems that move people, data, and goods around the world. After nearly seventy years of relying on the same classic ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Stock jumps over 103% on standout mid-stage trial data for oral obesity drug aleniglipron. Phase 2b shows 11.3%–15.3% placebo-adjusted weight loss, fueling investor optimism. Clean safety profile ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...